Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$98.87

-1.67 (-1.66%)

, PFE

Pfizer

$33.93

0.21 (0.62%)

10:25
10/05/16
10/05
10:25
10/05/16
10:25

Piper Jaffray biopharma analysts hold an analyst/industry conference call

Biopharmaceuticals Analysts Breazzano and Schimmer discuss PARP inhibitors, with a comprehensive look at the PARPi field in ovarian cancer and the role of PARPi in the ovarian treatment paradigm on an Analyst/Industry conference call that has been rescheduled to October 4 at 2 pm.

TSRO

Tesaro

$98.87

-1.67 (-1.66%)

PFE

Pfizer

$33.93

0.21 (0.62%)

CLVS

Clovis

$34.76

-0.59 (-1.67%)

BGNE

BeiGene

$30.71

-0.29 (-0.94%)

AZN

AstraZeneca

$32.67

0.1 (0.31%)

ABBV

AbbVie

$63.68

0.68 (1.08%)

  • 07

    Oct

  • 08

    Oct

  • 01

    Nov

  • 06

    Nov

  • 16

    Nov

  • 11

    Jan

  • 23

    Feb

TSRO Tesaro
$98.87

-1.67 (-1.66%)

09/26/16
BOFA
09/26/16
NO CHANGE
Target $109
BOFA
Buy
TESARO price target raised to $109 from $95 at BofA/Merrill
BofA/Merrill analyst Doug Leggate raised Teseor's price target to $109 from $95 following management meetings that suggest current EBITDA is about $800M, ahead of management targets. Shares are Buy rated.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Outperform
PARP addition makes sense for Eli Lilly oncology, says Leerink
In the wake of recent speculation that Eli Lilly (LLY) has expressed interest in acquiring Clovis (CLVS), Leerink analyst Seamus Fernandez says the addition of a PARP inhibitor makes strategic sense, fitting in "extremely well" with the former's oncology portfolio. Further, the analyst believes that the "impressive" emerging data from the PARP inhibitor class is likely to place both TESARO (TSRO) and Clovis high on the list of potential M&A targets. Fernandez reiterates an Outperform rating on Eli Lilly's shares.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
RHCO
09/21/16
NO CHANGE
Target $38
RHCO
Buy
Clovis well positioned for upside amid M&A speculation, says SunTrust
SunTrust analyst Peter Lawson attributes yesterday's afternoon rally in shares of Clovis Oncology (CLVS) to speculation of unconfirmed takeover interest from Eli Lilly (LLY). Clovis is a "pure play in one of the hottest areas of oncology" and could take the lead in the treatment setting in ovarian cancer for PARP inhibitors, Lawson tells investors in a research note. He expects launch of Clovis PARP inhibitor rucaparib in early 2017. The company is well positioned for upside and as a potential takeover target, Lawson contends. He finds market commentary around the PARP inhibitor companies, such as Clovis and TESARO (TSRO), as not surprising. The analyst has a Buy rating on Clovis with a $38 price target. Credit Suisse this morning upgraded the shares to Outperform citing the potential for a buyout.
PFE Pfizer
$33.93

0.21 (0.62%)

08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
CLVS Clovis
$34.76

-0.59 (-1.67%)

10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
09/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the risk in the shares is "less than what the market assumes." 2. Barclays (BCS) upgraded to Buy from Hold at HSBC citing the pending disposal of non-core businesses and resulting value creation. 3. Etsy (ETSY) upgraded to Buy from Neutral at Monness Crespi with the firm's analyst believing that Etsy shares can still move higher and sees a solid opportunity for upward revisions from improving conversion rates due to enhanced search and mobile functionality, expanding take rates, and advanced cross-boarder commerce capabilities with vendors. 4. Clovis (CLVS) upgraded to Outperform from Neutral at Credit Suisse with analyst Kennen MacKay saying the potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition." 5. Jabil Circuit (JBL) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying the company's cash flow is nearing an inflection amid an upturn in its Apple (AAPL) business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BGNE BeiGene
$30.71

-0.29 (-0.94%)

02/29/16
MSCO
02/29/16
INITIATION
Target $39
MSCO
Overweight
BeiGene initiated with an Overweight at Morgan Stanley
Target $39.
02/29/16
COWN
02/29/16
INITIATION
COWN
Outperform
BeiGene initiated with an Outperform at Cowen
Cowen initiated BeiGene with an Outperform rating as the company has proof-of-concept data on each of four clinical candidates and plans to monetize these assets on the global stage, in China, and via drug-drug combinations. Cowen expects BeiGene shares to appreciate as these candidates advance.
02/29/16
02/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Brian Ossenbeck initiated a cautious outlook for the North American truckload sector, saying he believes "tepid" freight demand and a lack of a boost to consumer spending from low gas prices will lead the first contraction in realized revenue per loaded mile since 2007. Ossenteck initiated Werner (WERN) with an Overweight rating due to expectations that its diversification will drive a re-rating of its shares. The analyst set a Neutral rating on Swift Transport (SWFT) and Ryder (R), and an Underweight rating on Heartland Express (HTLD) and Knight Transportation (KNX). 2. Editas Medicine (EDIT) initiated with an Outperform at Cowen and JMP Securities, and a Neutral at JPMorgan. Cowen cited the company's "world-class expertise" in CRISPR, which will enable the development of a broad pipeline. JPMorgan analyst Cory Kasimov added that the company's CRISPR gene editing platform has the potential to be a game changer, but that it has "limited value-inflecting news" likely to come in 2016. 3. BeiGene (BGNE) initiated with an Outperform at Cowen citing the proof-of-concept data on each of four clinical candidates and expects to monetize those assets on the global stage. The company was also initiated with an Overweight and a Buy at Morgan Stanley and Goldman, respectively. 4. Nielsen (NLSN) initiated with a Buy at Jefferies by analyst Ryan Cary, who said the company is well positioned to benefit from demand for cross-platform viewership measurement and greenfield in emerging markets provides protection against macro headwinds. 5. Square (SQ) initiated with a Sector Weight at Pacific Crest by analyst Josh Beck, who said his optimism is balanced by the market's high expectations for execution, the uncertain regulatory environment for SMB lending, and software initiatives. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
09/22/16
MAXM
09/22/16
INITIATION
Target $41
MAXM
Buy
BeiGene initiated with a Buy at Maxim
Maxim analyst Gabrielle Zhou initiated BeiGene with a Buy and a $41 price target. The analyst said BeiGene's BTK inhibitor, BGB-3111, is a de-risked, high-value asset, and based on its clinical profile and scarcity value, supports BeiGene's valuation and potential as the company works to bring the next BTK to market.
AZN AstraZeneca
$32.67

0.1 (0.31%)

09/12/16
09/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Buy from Neutral at SunTrust with analyst Robert Peck saying he thinks that a new interactive offering by the company could raise its contribution profit by 4%-9% and that the Street's 2017 estimates for the company "seem conservative." The analyst added that he thinks it's "very possible" that Pandora will be acquired. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying the company's MYSTIC oncology study could drive 39% share upside if successful. 3. Apache (APA) and upgraded to Overweight from Neutral at Atlantic Equities and to Peer Perform from Underperform at Wolfe Research. 4. Philip Morris (PM) upgraded to Conviction Buy from Neutral at Goldman with analyst Judy Hong saying she is increasingly bullish on the prospects of Next Generation Products and expects them to contribute 5%-6% of earnings by 2020. 5. Wal-Mart (WMT) upgraded to Outperform from Market Perform at Cowen with analysts led by Oliver Chen saying price investments, integration of physical and digital, and the Jet acquisitions position the company to regain its dominance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABBV AbbVie
$63.68

0.68 (1.08%)

10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.

TODAY'S FREE FLY STORIES

PPC

Pilgrim's Pride

$28.91

-0.63 (-2.13%)

09:07
09/20/17
09/20
09:07
09/20/17
09:07
Conference/Events
Pilgrim's Pride holds an investor day »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MSFT

Microsoft

$75.44

0.28 (0.37%)

, GD

General Dynamics

$203.12

0.94 (0.46%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
Microsoft General Dynamics and Dell EMC awarded $1B Air Force contract »

General Dynamics (GD),…

MSFT

Microsoft

$75.44

0.28 (0.37%)

GD

General Dynamics

$203.12

0.94 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

JAGX

Jaguar Health

$0.38

-0.02 (-5.00%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
Jaguar Health's Canalevia qualifies as 'minor use' for EID in dogs »

Jaguar Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOS

MYOS

$1.59

0.28 (21.37%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
MYOS names Joseph Mannello as CEO, effective August 24 »

MYOS RENS Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:05
09/20/17
09/20
09:05
09/20/17
09:05
General news
U.S. equities are stuck in the Fed's headlights »

U.S. equities are stuck…

SGMS

Scientific Games

$43.10

1.05 (2.50%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Scientific Games to acquire NYX Gaming Group for C$2.40 per share »

Scientific Games and NYX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

PG

Procter & Gamble

$94.17

1.02 (1.10%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Trian: Initiatives will make P&G 'best-in-class company once again' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$52.09

-4.48 (-7.92%)

09:03
09/20/17
09/20
09:03
09/20/17
09:03
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Breaking Hot Stocks news story on Rent-A-Center »

Rent-A-Center says August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$13.63

0.18 (1.34%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
American Eagle to expand to India through licensed stores »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

, GOOG

Alphabet

$921.81

6.81 (0.74%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Periodicals
Google said to acquire certain HTC assets, VentureBeat's Bass reports »

VentureBeat reporter Evan…

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Rent-A-Center reports core U.S. SSS down 5.3% in August »

Rent-A-Center, announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

09:01
09/20/17
09/20
09:01
09/20/17
09:01
Conference/Events
Meet Group to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EDVMF

Endeavour Mining

$18.42

-0.0721 (-0.39%)

09:00
09/20/17
09/20
09:00
09/20/17
09:00
Conference/Events
Endeavour Mining holds a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Hot Stocks
General Mills says cereal sales improved in August »

Expects to improve yogurt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CIEN

Ciena

$22.08

-0.26 (-1.16%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
Ciena analyst commentary  »

Ciena FY18 growth more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

FDX

FedEx

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

BPMC

Blueprint Medicines

$63.86

0.98 (1.56%)

08:56
09/20/17
09/20
08:56
09/20/17
08:56
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.86

0.16 (0.65%)

, S

Sprint

$8.20

0.52 (6.77%)

08:55
09/20/17
09/20
08:55
09/20/17
08:55
Options
Notable open interest changes for September 20th »

Tuesday's total…

BAC

Bank of America

$24.86

0.16 (0.65%)

S

Sprint

$8.20

0.52 (6.77%)

T

AT&T

$38.21

0.79 (2.11%)

BABA

Alibaba

$180.07

0.09 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

  • 16

    May

RARE

Ultragenyx

$51.90

-1.09 (-2.06%)

08:54
09/20/17
09/20
08:54
09/20/17
08:54
Conference/Events
Ultragenyx has a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

WBC

Wabco

$146.87

3.9 (2.73%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Conference/Events
Wabco holds a conference call »

Chairman & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$156.60

0.83 (0.53%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAN

Aaron's

$39.35

0.94 (2.45%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Aaron's analyst commentary  »

Aaron's weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Earnings
General Mills says sees FX having 1c favorable impact to FY18 EPS 

FY18 EPS consensus $3.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.